Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 80-87 , September 2010

Cardiac Disease in Cancer Patients: An Overview

References 

  1. Hampton T. Cancer therapy can be hard on the heart: researchers aim to explain—and avoid—cardiotoxicity. JAMA. 2010;303:1019–1020
  2. Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102:14–25
  3. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26:5204–5212
  4. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7:332–344
  5. Sereno M, Brunello A, Chiappori A, et al. Cardiac toxicity: old and new issues in anti-cancer drugs. Clin Transl Oncol. 2008;10:35–46
  6. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol. 2007;25:4952–4960
  7. Lenihan DJ, Esteva FJ. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. Oncologist. 2008;13:1224–1234
  8. Lenihan DJ. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?. J Clin Oncol. 2008;26:5154–5155
  9. Dolci A, Dominici R, Cardinale D, et al. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity. Am J Clin Pathol. 2008;130:688–695
  10. Garg R, Yusuf S, et al. Collaborative Group on ACE Inhibitor Trials Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450–1456
  11. Bari 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503–2515
  12. Killip T, Passamani E, Davis K. Coronary artery surgery study (CASS): a randomized trial of coronary bypass surgery. Eight years follow-up and survival in patients with reduced ejection fraction. Circulation. 1985;72:V102–V109
  13. Chaitman BR, Ryan TJ, Kronmal RA, et al. Coronary Artery Surgery Study (CASS): comparability of 10 year survival in randomized and randomizable patients. J Am Coll Cardiol. 1990;16:1071–1078
  14. Popat S, Smith IE. Therapy insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects. Nat Clin Prac Oncol. 2008;5:324–335
  15. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003;107:2446–2452
  16. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006;24:4107–4115
  17. Dibbs Z, Kurrelmeyer K, Kalra D, et al. Cytokines in heart failure: pathogenetic mechanisms and potential treatment. Proc Assoc Am Physicians. 1999;111:423–428
  18. Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest. 1994;105:897–904
  19. Tamariz L, Hare JM. Inflammatory cytokines in heart failure: roles in aetiology and utility as biomarkers. Eur Heart J. 2010;31:768–770
  20. Yan AT, Yan RT, Cushman M, et al. Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. Eur Heart J. 2010;31:875–882
  21. Godkar D, Bachu K, Dave B, et al. Comparison and co-relation of invasive and noninvasive methods of ejection fraction measurement. J Natl Med Assoc 2007;99:1227-1228, 31-34.
  22. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004;43:317–327
  23. Hernandez AF, Hammill BG, O'Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol. 2009;53:184–192
  24. Vitarelli A, Tiukinhoy S, Di Luzio S, et al. The role of echocardiography in the diagnosis and management of heart failure. Heart Fail Rev. 2003;8:181–189
  25. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007;50:2173–2195
  26. Kelley WE, Januzzi JL, Christenson RH. Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure. Clin Chem. 2009;55:2098–2112
  27. Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:e1–e90
  28. de Lemos JA, Mcguire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362:316–322
  29. Cil T, Kaplan AM, Altintas A, et al. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series. Clin Drug Investig. 2009;29:131–137
  30. Burjonroppa SC, Tong AT, Xiao LC, et al. Cancer patients with markedly elevated B-type natriuretic peptide may not have volume overload. Am J Clin Oncol. 2007;30:287–293
  31. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111:2837–2849
  32. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717
  33. Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. 2000;57:1408–1411
  34. Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Biol. 2004;217:53–58
  35. Tornio A, Pasanen MK, Laitila J, et al. Comparison of 3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol. 2005;97:104–108
  36. Karp I, Behlouli H, Lelorier J, et al. Statins and cancer risk. Am J Med. 2008;121:302–309
  37. Goldstein MR, Mascitelli L. Do statins decrease cardiovascular disease at the expense of increasing cancer?. Int J Cardiol. 2009;133:254–255
  38. Khaidakov M, Wang W, Khan JA, et al. Statins and angiogenesis: is it about connections?. Biochem Biophys Res Commun. 2009;387:543–547
  39. Yang X, So WY, Ma RC, et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care. 2009;32:1826–1832
  40. Singh H, Mahmud SM, Turner D, et al. Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol. 2009;104:3015–3023
  41. Bil J, Zapala L, Nowis D, et al. Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. Cancer Lett. 2010;288:57–67
  42. Elewa HF, El-Remessy AB, Somanath PR, et al. Diverse effects of statins on angiogenesis: new therapeutic avenues. Pharmacotherapy. 2010;30:169–176
  43. Gonyeau MJ, Yuen DW. A clinical review of statins and cancer: helpful or harmful?. Pharmacotherapy. 2010;30:177–194
  44. Bertagnolli MM, Hsu M, Hawk ET, et al. Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res. 2010;3:588–596
  45. Mehta NG, Mehta M. Overcoming multidrug-resistance in cancer: statins offer a logical candidate. Med Hypotheses. 2010;74:237–239
  46. Jakobisiak M, Golab J. Statins can modulate effectiveness of antitumor therapeutic modalities. Med Res Rev. 2010;30:102–135
  47. Khemasuwan D, Divietro ML, Tangdhanakanond K, et al. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med. 2010;123:60–65
  48. Couzin J. Drug safety: FDA panel urges caution on many anti-inflammatory drugs. Science. 2005;307:1183a–5183a
  49. Borer JS, Pouleur H, Abadie E, et al. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. Eur Heart J. 2007;28:1904–1909
  50. Serebruany VL. Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens?. Fundam Clin Pharmacol. 2009;23:411–417
  51. Powe DG, Voss MJ, Habashy HO, et al. Beta-blocker treatment is associated with a reduction in tumour metastasis and an improvement in specific survival in patients with breast cancer. Supplements Eur J Cancer. 2010;8:188;Presented at 7th European Breast Cancer Conference, Barcelona, Spain, March 2010
  52. “The Bypass Angioplasty Revascularization Investigation Investigators”. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996;335:217–225
  53. King SB, Smith SC, Hirshfeld JW, et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. J Am Coll Cardiol. 2008;51:172–209
  54. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2007;116:e418–e499
  55. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519–1521
  56. Heir JS, Gottumukkala V, Singh M, et al. Coronary stents and noncardiac surgery: current clinical challenges and conundrums. Prev Cardiol. 2010;13:8–13
  57. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol. 2006;48:1–11
  58. Noble SI, Shelley MD, Coles B, et al. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9:577–584
  59. Lee AYY, Levine MN, Baker RI, et al. Low–molecular-weight Heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153
  60. Maisch B, Seferovic PM, Ristic AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary: the Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. Eur Heart J. 2004;25:587–610
  61. Tsang TS, Freeman WK, Sinak LJ, et al. Echocardiographically guided pericardiocentesis: evolution and state-of-the-art technique. Mayo Clin Proc. 1998;73:647–652
  62. Tsang TSM, Enriquez-Sarano M, Freeman WK, et al. Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc. 2002;77:429–436
  63. Hidalgo JD, Krone R, Rich MW, et al. Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2004;34:615–619
  64. Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112:2500–2508

PII: S0033-0620(10)00090-3

doi: 10.1016/j.pcad.2010.05.004

Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 80-87 , September 2010

Article Tools

* Image Usage & Resolution